References
- Nebert D W., Nelson D R., Coon M J., Estabrook R W., Feyereisen R, Fujii-Kuriyama Y, Gonzalez F J., Guengerich FP, Gunsalus I C., Johnson E F., Loper J C., Sato R, Waterman M R., Waxman D J. The P450 superfamily: update on new sequences, gene mapping, and recommended nomenclature. DNA and Cell Biol 1991; 10: 1–14
- Mahgoub A, Idle J R., Dring L G., Lancaster R, Smith R L. Polymorphic hydroxylation of debrisoquine in man. Lancet 1977; 2: 584–6
- Eichelbaum M, Spannbucker N, Steincke B, Dengler H J. Defective N-oxidation of sparteine in man: a new pharmacogenetic defect. Eur J Clin Pharmacol 1979; 16: 183–7
- Alván G, Bechtel P, Iselius L, Gundert-Remy U. Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations. Eur J Clin Pharmacol 1990; 39: 533–7
- Zanger U M., Vilbois F, Hardwick J P., Meyer U A. Absence of hepatic cytochrome P450bufl causes genetically deficient debrisoquine oxidation in man. Biochemistry 1988; 27: 5447–54
- Brøsen K, Otton S V., Gram L F. Sparteine oxidation polymorphism in Denmark Acta Pharmacol Toxicol 1985; 57: 357–60
- Heim M, Meyer U A. Genotyping of poor metabolisers of debrisoquine by allelespecific PCR amplification. Lancet 1990; 336: 529–32
- Küpfer A, Preisig R. Pharmacogenetics of mephenytoin: a new drug hydrxylation polymorphism in man. Eur J Clin Pharmacol 1984; 26: 753–9
- Wedlund P J., Aslanian W S., McAllister C B., Wilkinson G R., Branch R A. Mephenytoin hydroxylation deficiency in Caucasians: frequency of a new oxidative drug metabolism polymorphism. Clin Pharmacol Ther 1984; 36: 773–80
- Romkes M, Faletto M B., Blaisdell J A., Raucy J L., Goldstein J A. Cloning and expression of complementary DNAs for multiple members of the human P450IIC subfamily. Biochemistry 1991; 30: 3247–55
- Butler M A., Iwasaki M, Guengereich F P., Kadlubar F F. Human cytochrome P-450pa (P-450IA2), the phenacetin O-deethylase, is primarily responsible for the hepatic 3-demethylation of caffeine and N-oxidation of carcinogenic arylamines. Proc Natl Acad Sci USA 1989; 86: 7696–700
- Sesardic D, Boobis A R., Edwards R J., Davies D S. A form of cytochrome P450 in man, orthologous to form d in the rat, catalyses the O-deethylation of phenacetin and is inducible by cigarette smoking. Br J Clin Pharmacol 1988; 26: 363–72
- Sesardic D, Boobis A R., Murray B P., Murray S, Segura J, Torre R DL, Davies D S. Furafylline is a potent selective inhibitor of cytochrome P450IA2 in man. Br J Clin Pharmacol 1990; 29: 651–63
- Brøsen K, Skjelbo E, Rasmussen B B., Poulsen H E., Loft S. fluvoxamine is a potent inhibitor of cytochrome P450IA2. Biochem Pharmacol 1993; 45: 1211–4
- Kalow W, Tang B-K. Use of caffeine metabolite ratios to explore CYP1A2 and xanthine oxidase activities. Clin Pharmacol Ther 1991; 50: 508–19
- Koop D R. Oxidative and reductive metabolism by cytochrome P450 2E1. FASEB J 1992; 6: 724–30
- Watkins P B., Turgeon D K., Saenger P, Lown K S., Kolars J C., Hamilton T, Fishman K, Guzelias P S., Voorhees J J. Comparison of urinary 6-β-cortisol and the erythromycin breath test as measures of hepatic P450IIIA (CYP3A) activity. Clin Pharmacol Ther 1992; 52: 265–73
- Ward S A., Helsby N A., Skjelbo E, Brøsen K, Gram L F., Breckenridge A M. The activation of the bigunide antimalarial proguanil co-segregates with the mephenytoin oxidation polymorphism—a panel study. Br J Clin Pharmacol 1991; 31: 689–92
- Brøsen K, Gram L F. Clinical significance of the sparteine/debrisoquine oxidation polymorphism. Eur J Clin Pharmacol 1989; 36: 537–47
- Brøsen K. Recent developments in hepatic drug oxidation. Implication for clinical pharmacokinetics. Clin Pharmacokinet 1990; 18: 220–39
- Sperber A D. Toxic interaction between fluvoxamine and substained release theophylline in an 11-year-ole boy. Drug Safety 1991; 6: 460–2
- Bertchy G, Vandel S, Vandel B, Alters G, Volmat R. Fluvoxamine-tricyclic antidepressant interaction. Eur J Clin Pharmacol 1991; 40: 119–20
- Spina E, Campo G M., Avenosa A, Pollicino M A., Caputi A P. Interaction between fluvoxamine and imipramine/desipramine in four patients. Ther Drug Monit 1992; 14: 194–6
- Gram L F., Overø KF. Drug interaction: inhibitory effect of neuroleptics on the metabolism of tricyclic antidepressants in man. Br Med J 1972; 163: 463–5
- Bell I R., Cole J O. Fluvoxetine induces elevation of desipramine level and exacerbation and geriatric non-psychotic depression. J Clin Psychopharmacol 1988; 8: 447–8
- Brøsen K, Hansen J G., Nielsen K K., Sindrup S H., Gram L F. Inhibition of paroxetine of desipramine metabolism in extensive but not in poor metabolisers of spariteine. Eur J Pharmacol, in press